Arrowhead Pharmaceuticals Ownership
| ARWR Stock | USD 19.56 0.54 2.84% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 124 M | Current Value 120 M | Avarage Shares Outstanding 63.5 M | Quarterly Volatility 40.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Arrowhead |
Arrowhead Stock Ownership Analysis
About 80.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings (P/E) ratio of 482.39. Arrowhead Pharmaceuticals recorded a loss per share of 5.14. The entity last dividend was issued on the 29th of October 2010. The firm had 1:10 split on the 17th of November 2011. Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. Arrowhead Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 329 people. For more info on Arrowhead Pharmaceuticals please contact Christopher Anzalone at 626 304 3400 or go to https://arrowheadpharma.com.Besides selling stocks to institutional investors, Arrowhead Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Arrowhead Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Arrowhead Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Arrowhead Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Arrowhead Pharmaceuticals Insider Trades History
About 4.0% of Arrowhead Pharmaceuticals are currently held by insiders. Unlike Arrowhead Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Arrowhead Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Arrowhead Pharmaceuticals' insider trades
Arrowhead Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Arrowhead Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arrowhead Pharmaceuticals backward and forwards among themselves. Arrowhead Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Arrowhead Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Woodline Partners Lp | 2024-09-30 | 865.8 K | Western Financial Corp/ca | 2024-09-30 | 820.2 K | Millennium Management Llc Usd | 2024-09-30 | 645.6 K | Millennium Management Llc Usd | 2024-09-30 | 645.6 K | Bank Of America Corp | 2024-09-30 | 578.8 K | Blackrock Inc | 2024-09-30 | 15.8 M | Vanguard Group Inc | 2024-09-30 | 12.2 M | Venbio Select Advisor Llc | 2024-09-30 | 8.9 M | Fidelity Management And Research Company | 2024-09-30 | 6.1 M | T. Rowe Price Investment Management,inc. | 2024-09-30 | 3.6 M | Geode Capital Management, Llc | 2024-09-30 | 3 M |
Arrowhead Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arrowhead Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arrowhead Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arrowhead Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arrowhead Pharmaceuticals Outstanding Bonds
Arrowhead Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Arrowhead Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Arrowhead bonds can be classified according to their maturity, which is the date when Arrowhead Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| International Game Technology Corp BondUS460599AD57 | View |
Arrowhead Pharmaceuticals Corporate Filings
F4 | 7th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 20th of December 2024 Other Reports | ViewVerify | |
8K | 18th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 26th of November 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Pair Trading with Arrowhead Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.
The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.